AR129635A2 - Moduladores de tetrahidropiridopirazina de gpr6 - Google Patents
Moduladores de tetrahidropiridopirazina de gpr6Info
- Publication number
- AR129635A2 AR129635A2 ARP230101544A ARP230101544A AR129635A2 AR 129635 A2 AR129635 A2 AR 129635A2 AR P230101544 A ARP230101544 A AR P230101544A AR P230101544 A ARP230101544 A AR P230101544A AR 129635 A2 AR129635 A2 AR 129635A2
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- alkyl
- cycloalkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención proporciona compuestos de fórmula (1) que son útiles como moduladores de GPR6, sus composiciones farmacéuticas, los métodos para el tratamiento de afecciones asociadas con GPR6, los procesos para realizar los compuestos y sus intermediarios. Reivindicación 1: El compuesto de fórmula (1), caracterizado porque R¹ se selecciona del grupo que consiste en cicloalquilo C₃₋₈ opcionalmente sustituido, heterociclilo C₃₋₆ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido y heteroarilo C₁₋₁₀ opcionalmente sustituido; X¹ es N y X² es CH; o X¹ es CH y X² es N; o X¹ es N y X² es N; cuando X¹ es N, Z se selecciona del grupo que consiste en alquileno C₁₋₆, haloalquileno C₁₋₆, -C(O)-, y -S(O)₂-; cuando X¹ es CH, Z se selecciona del grupo que consiste en alquileno C₁₋₆, haloalquileno C₁₋₆, -O-, -C(O)-, -NH-, -S-, -S(O)- y -S(O)₂-; q es 0, 1 o 2; s es 0, 1 o 2; R² es -OR⁵ o -NR⁶R⁷; R³, cada vez que se toma, se selecciona de forma independiente del grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₈ y trifluorometilo; p es 0, 1 o 2; R⁴, cada vez que se toma, se selecciona de forma independiente del grupo que consiste en alquilo C₁₋₆, hidroxi y halo; r es 0 o 1; R⁵ se selecciona del grupo que consiste en alquilo C₁₋₆ y cicloalquilo C₃₋₈; R⁶ se selecciona del grupo que consiste en hidrógeno y alquilo C₁₋₆; R⁷ se selecciona del grupo que consiste en alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈, arilo C₆₋₁₀ opcionalmente sustituido, heteroarilo C₁₋₁₀ opcionalmente sustituido y heterociclilo C₃₋₆ opcionalmente sustituido; X³ se selecciona del grupo que consiste en CH y CR⁴ y X⁴ es NR⁸; o X³ es NR⁸ y X⁴ se selecciona del grupo que consiste en CH y CR⁴; R⁸ se selecciona del grupo que consiste en alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₈, -S(O)₂-R⁹, -C(O)-R¹⁰, -C(O)-N(R¹¹)(R¹²) y -C(O)-OR¹³; R⁹ se selecciona del grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₈ y fenilo opcionalmente sustituido; R¹⁰ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₈, arilo C₆₋₁₀ opcionalmente sustituido, heteroarilo C₁₋₁₀ opcionalmente sustituido y heterociclilo C₃₋₆ opcionalmente sustituido; R¹¹ se selecciona del grupo que consiste en hidrógeno y alquilo C₁₋₆; R¹² se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆ y cicloalquilo C₃₋₈; o R¹¹ y R¹² se toman entre sí con el nitrógeno al que se unen para formar un anillo saturado de 4 a 7 miembros que tiene opcionalmente 1 heteroátomo en el anillo adicional que se selecciona del grupo N, O y S y se sustituye opcionalmente sobre cualquiera de los átomos de carbono del anillo con 1 a 5 sustituyentes que se seleccionan de forma independiente del grupo que consiste en ciano, halo, hidroxi, amino, heterociclilo C₃₋₆ opcionalmente sustituido, amida C₁₋₉, alquilo C₁₋₆ opcionalmente sustituido y alcoxi C₁₋₄ y se sustituye sobre cualquier nitrógeno en el anillo adicional por un sustituyente que se selecciona del grupo que consiste en hidrógeno, cicloalquilo C₃₋₈ y alquilo C₁₋₆ opcionalmente sustituido; R¹³ se selecciona del grupo que consiste en alquilo C₁₋₆ y cicloalquilo C₃₋₈; o su sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919661P | 2013-12-20 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129635A2 true AR129635A2 (es) | 2024-09-11 |
Family
ID=52440811
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104807A AR098872A1 (es) | 2013-12-20 | 2014-12-19 | Moduladores de tetrahidropiridopirazinas de gpr6 |
| ARP230101544A AR129635A2 (es) | 2013-12-20 | 2023-06-15 | Moduladores de tetrahidropiridopirazina de gpr6 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104807A AR098872A1 (es) | 2013-12-20 | 2014-12-19 | Moduladores de tetrahidropiridopirazinas de gpr6 |
Country Status (42)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977837B2 (ja) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| JP6193374B2 (ja) | 2012-08-13 | 2017-09-06 | 武田薬品工業株式会社 | Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体 |
| NZ743463A (en) | 2012-08-28 | 2019-09-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX366123B (es) | 2013-02-28 | 2019-06-27 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| CN105960400B (zh) | 2013-05-17 | 2019-05-31 | 爱尔兰詹森科学公司 | 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| EP3060547B1 (en) | 2013-10-23 | 2017-10-11 | Janssen Sciences Ireland UC | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US20150216938A1 (en) | 2014-02-05 | 2015-08-06 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
| CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| US10179783B2 (en) * | 2014-02-14 | 2019-01-15 | Taketa Pharmaceutical Company Limited | Tetrahydropyridopyrazines as modulators of GPR6 |
| CN107847762A (zh) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| CN109640980A (zh) | 2016-04-15 | 2019-04-16 | 诺维拉治疗公司 | 包含壳体装配抑制剂的组合和方法 |
| JOP20180057A1 (ar) * | 2017-06-15 | 2019-01-30 | Takeda Pharmaceuticals Co | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
| CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| JP2022521081A (ja) | 2019-02-22 | 2022-04-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体 |
| MA55879A (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804575A1 (en) * | 1994-08-11 | 1997-11-05 | Takeda Chemical Industries, Ltd. | G protein coupled receptor protein, production, and use thereof |
| KR20020015307A (ko) * | 1999-02-26 | 2002-02-27 | 리처드 피. 버군 쥬니어 | Ｇ 단백질 결합 수용체 ６의 소형 분자 조절제 |
| WO2001070269A1 (en) | 2000-03-24 | 2001-09-27 | Akzo Nobel N.V. | Keratinocyte growth inhibitors and hydroxamic acid derivatives |
| WO2004038416A1 (en) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6) |
| JP2006516573A (ja) | 2003-01-31 | 2006-07-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体 |
| SE0400285D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| HRP20110539T1 (hr) * | 2006-04-21 | 2011-08-31 | Pfizer Products Inc. | PIRIDINO[3,4-b]PIRAZINONI |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| JP5390513B2 (ja) | 2007-06-05 | 2014-01-15 | アストリウム・リミテッド | 遠隔検査システム及び方法 |
| GB0710844D0 (en) | 2007-06-06 | 2007-07-18 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| GB2449929A (en) | 2007-06-08 | 2008-12-10 | Snell & Wilcox Ltd | Hierarchical spatial resolution building processes to fill holes in an interpolated image |
| MX353776B (es) | 2009-06-12 | 2018-01-29 | Abivax | Compuestos utiles para tratar cancer. |
| WO2013087808A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin |
| WO2013087815A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof |
| AU2013259551B2 (en) | 2012-05-09 | 2017-11-02 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| JP6193374B2 (ja) * | 2012-08-13 | 2017-09-06 | 武田薬品工業株式会社 | Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体 |
| FR2995937B1 (fr) | 2012-09-21 | 2014-09-26 | Exoes | Ensemble de production d'electricite a moteur a pression de vapeur |
| JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
-
2014
- 2014-12-18 JO JOP/2014/0369A patent/JO3466B1/ar active
- 2014-12-19 DK DK14833425.3T patent/DK3083620T3/en active
- 2014-12-19 AU AU2014368992A patent/AU2014368992C1/en active Active
- 2014-12-19 TN TN2016000244A patent/TN2016000244A1/en unknown
- 2014-12-19 EP EP14833425.3A patent/EP3083620B1/en active Active
- 2014-12-19 CA CA2934247A patent/CA2934247C/en active Active
- 2014-12-19 CR CR20160321A patent/CR20160321A/es unknown
- 2014-12-19 TR TR2019/00038T patent/TR201900038T4/tr unknown
- 2014-12-19 SG SG11201604921TA patent/SG11201604921TA/en unknown
- 2014-12-19 SM SM20180668T patent/SMT201800668T1/it unknown
- 2014-12-19 PL PL14833425T patent/PL3083620T3/pl unknown
- 2014-12-19 JP JP2016541330A patent/JP6538697B2/ja active Active
- 2014-12-19 ES ES14833425T patent/ES2702187T3/es active Active
- 2014-12-19 PT PT14833425T patent/PT3083620T/pt unknown
- 2014-12-19 KR KR1020167019644A patent/KR102441531B1/ko active Active
- 2014-12-19 WO PCT/US2014/071543 patent/WO2015095728A1/en not_active Ceased
- 2014-12-19 HU HUE14833425A patent/HUE042443T2/hu unknown
- 2014-12-19 HR HRP20182004TT patent/HRP20182004T1/hr unknown
- 2014-12-19 CN CN201480069550.7A patent/CN105829309B/zh active Active
- 2014-12-19 AR ARP140104807A patent/AR098872A1/es active IP Right Grant
- 2014-12-19 NZ NZ721723A patent/NZ721723A/en unknown
- 2014-12-19 MA MA39193A patent/MA39193B1/fr unknown
- 2014-12-19 EA EA201691272A patent/EA032443B1/ru unknown
- 2014-12-19 GE GEAP201414210A patent/GEP201706783B/en unknown
- 2014-12-19 MY MYPI2016001142A patent/MY177031A/en unknown
- 2014-12-19 EP EP18187138.5A patent/EP3453709A1/en not_active Withdrawn
- 2014-12-19 RS RS20181548A patent/RS58092B1/sr unknown
- 2014-12-19 BR BR112016014020-6A patent/BR112016014020B1/pt active IP Right Grant
- 2014-12-19 PE PE2016000838A patent/PE20160751A1/es unknown
- 2014-12-19 SI SI201430995T patent/SI3083620T1/sl unknown
- 2014-12-19 TW TW110118089A patent/TWI809395B/zh active
- 2014-12-19 UA UAA201606659A patent/UA120427C2/uk unknown
- 2014-12-19 CN CN201810356710.6A patent/CN108658978A/zh active Pending
- 2014-12-19 US US14/577,480 patent/US9181249B2/en active Active
- 2014-12-19 LT LTEP14833425.3T patent/LT3083620T/lt unknown
- 2014-12-19 UY UY0001035908A patent/UY35908A/es not_active Application Discontinuation
- 2014-12-19 TW TW103144660A patent/TWI730937B/zh active
- 2014-12-19 MX MX2016008188A patent/MX2016008188A/es active IP Right Grant
-
2015
- 2015-10-14 US US14/883,174 patent/US9708313B2/en active Active
-
2016
- 2016-06-13 IL IL24617716A patent/IL246177B/en active IP Right Grant
- 2016-06-17 DO DO2016000144A patent/DOP2016000144A/es unknown
- 2016-06-17 PH PH12016501192A patent/PH12016501192A1/en unknown
- 2016-06-20 CL CL2016001595A patent/CL2016001595A1/es unknown
- 2016-07-08 ZA ZA2016/04703A patent/ZA201604703B/en unknown
- 2016-07-20 EC ECIEPI201661758A patent/ECSP16061758A/es unknown
-
2017
- 2017-06-13 US US15/621,761 patent/US10077266B2/en active Active
-
2018
- 2018-08-07 US US16/057,350 patent/US10738046B2/en active Active
-
2019
- 2019-01-03 CY CY20191100008T patent/CY1121395T1/el unknown
-
2023
- 2023-06-15 AR ARP230101544A patent/AR129635A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| AR107912A1 (es) | Inhibidores de ret | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| AR098432A1 (es) | Compuestos heterocíclicos | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR099970A1 (es) | Amidas, carbamatos y ureas que contienen carbazol como moduladores de criptocromo | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR092319A1 (es) | Carbazoles que contienen sulfonamidas como moduladores de criptocromo | |
| AR095351A1 (es) | Inhibidores de histona desacetilasa (hdac) | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR110440A1 (es) | Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina | |
| AR097948A1 (es) | Inhibidores de la proteasa de cisteína catepsina |